- Home
- ISPC vs CHRO Comparison
ISPC vs CHRO Comparison
Compare ISPC & CHRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ISPC
- CHRO
- Stock Information
- Founded
- ISPC 2009
- CHRO 2002
- Country
- ISPC United States
- CHRO United States
- Employees
- ISPC N/A
- CHRO N/A
- Industry
- ISPC Precision Instruments
- CHRO
- Sector
- ISPC Health Care
- CHRO
- Exchange
- ISPC Nasdaq
- CHRO Nasdaq
- Market Cap
- ISPC 4.7M
- CHRO 4.2M
- IPO Year
- ISPC 2021
- CHRO 2024
- Fundamental
- Price
- ISPC $3.86
- CHRO $0.60
- Analyst Decision
- ISPC
- CHRO Strong Buy
- Analyst Count
- ISPC 0
- CHRO 1
- Target Price
- ISPC N/A
- CHRO N/A
- AVG Volume (30 Days)
- ISPC 213.0K
- CHRO 121.3K
- Earning Date
- ISPC 11-07-2024
- CHRO 11-13-2024
- Dividend Yield
- ISPC N/A
- CHRO N/A
- EPS Growth
- ISPC N/A
- CHRO N/A
- EPS
- ISPC N/A
- CHRO N/A
- Revenue
- ISPC $10,390,702.00
- CHRO N/A
- Revenue This Year
- ISPC $13.82
- CHRO N/A
- Revenue Next Year
- ISPC $11.76
- CHRO N/A
- P/E Ratio
- ISPC N/A
- CHRO N/A
- Revenue Growth
- ISPC 0.74
- CHRO N/A
- 52 Week Low
- ISPC $2.76
- CHRO $0.45
- 52 Week High
- ISPC $12.20
- CHRO $6.00
- Technical
- Relative Strength Index (RSI)
- ISPC 35.78
- CHRO 48.49
- Support Level
- ISPC $2.76
- CHRO $0.55
- Resistance Level
- ISPC $4.66
- CHRO $0.71
- Average True Range (ATR)
- ISPC 0.40
- CHRO 0.10
- MACD
- ISPC -0.07
- CHRO -0.00
- Stochastic Oscillator
- ISPC 23.16
- CHRO 23.98
About ISPC iSpecimen Inc.
iSpecimen Inc is a technology-driven company focused on connecting life science researchers who need human biofluids, solid tissues, and hematopoietic stem and immune cells for their research, with the available biospecimens. The company generates revenue by procuring various specimens from hospitals, laboratories, and other supply sites. Geographically, it has a presence in the Americas; Europe, the Middle East, Africa, and Asia Pacific, which majority, comes from the Americas.
About CHRO Chromocell Therapeutics Corporation
Channel Therapeutics Corp is a clinical-stage biotechnology company developing and commercializing novel, non-opioid, non-addictive therapeutics to alleviate pain. The initial clinical focus is to selectively target the sodium ion channel known as NaV1.7 for the treatment of various types of chronic pain, acute and chronic eye pain, and post-surgical nerve blocks. Its pipeline includes CC8464 for ISFN and EM and CT2000 for Acute and CHronic Eye Pain-Dry Eye Disease.